A cold environment is a significant risk factor for cardiovascular diseases (CVDs), and its pathophysiological mechanisms involve complex interactions across multiple organ systems. However, the role of the liver as a central organ for metabolism and energy homeostasis in cold-related CVDs remains unclear. In this study, we systematically investigated the role of the liver in the pathogenesis of cardiac damage in cold regions by integrating clinical cohort studies, bioinformatic analysis, and animal experiments. The results demonstrated that in a cold-exposed population, serum alanine aminotransferase levels remained an independent risk factor for heart failure after adjusting for traditional cardiovascular risk factors. Transcriptomic analysis of liver tissues from chronically cold-exposed mice in a public database revealed that differentially expressed genes were significantly enriched in pathways related to lipid metabolism and cell cycle regulation. Animal experiments further confirmed that long-term cold exposure induced liver injury and dyslipidemia, accompanied by cardiac structural remodeling and myocardial injury. We identified and validated an activated hepatic cell cycle program through protein-protein interaction network analysis and Ki67 immunohistochemistry staining in cold-exposed mice. In vitro co-culture experiments further demonstrated that hepatocytes overexpressing cell cycle regulators induce cardiomyocyte injury through paracrine secretion of multiple factors. In summary, we identified liver injury as an independent risk factor for CVDs in cold regions and demonstrated that chronic cold stress induces liver metabolic dysregulation and aberrant activation of cell cycle signaling, which together contribute to cardiac injury through liver-heart crosstalk.

Atherosclerosis (AS) is a common complication of lung adenocarcinoma (LUAD), but its underlying mechanisms in LUAD remain unclear. This study aimed to decipher the role of chromatin regulators in AS pathogenesis and their association with clinical outcomes in LUAD patients. AS- and chromatin regulator (CR)-associated prognostic indicators were identified in LUAD and analyzed in the TCGA-LUAD cohort using Cox regression and Disease Ontology analysis. CR-related risk subgroups were defined by NMF in the GSE26939 cohort. GSVA and WGCNA, combined with interpretable machine learning, were used to construct a predictive model and identify key genes, which were validated in GSE68465. The molecular features of key genes and their roles in AS were further evaluated. Besides, mechanisms of key genes in M2-like macrophages were assessed at the single-cell level in LUAD patients using cutting-edge analytical frameworks. A deep learning framework and molecular docking were used to screen natural compounds. Finally, co-culture experiments were conducted for validation. CR signatures can guide the LUAD patients LUAD patients into high- and low-AS risk groups and were associated with clinical outcomes. LAIR1 can be considered as an AS-related factor enriched in M2-like macrophages and involved in LUAD progression. Quercetin was identified as potential preventive agent for AS in LUAD patients. CR-associated signatures play an important role in AS pathogenesis and LUAD progression.

BACKGROUND:This study aimed to investigate the efficacy and independent risk factors of sac filling with rifampin after endovascular repair for treating brucellosis-associated pseudoaneurysms. METHODS:This retrospective study included patients with brucellosis-associated pseudoaneurysms who underwent sac filling with rifampin after endovascular repair. Brucella activity was evaluated using C-reactive protein (CRP) and procalcitonin levels. The patients were followed up for 5 years. Intraoperative and postoperative complications, including paraplegia, endoleak, and stent thrombosis, and mortality were recorded. Kaplan-Meier survival curves were used to estimate the incidence of adverse events, and Cox regression analysis was performed to determine the independent risk factors for adverse events. RESULTS:A total of 30 patients were included in this study. The procedural success rate was 90%. The mean follow-up period was 51.9 ± 2.8 months. Kaplan-Meier survival analysis revealed that the overall 1-, 3-, and 5-year event-free survival rates were 93%, 80%, and 73%, respectively. Multivariate Cox regression analysis revealed that a preoperative CRP level ≥ 33.65 mg/L and the percentage of neutrophils were independent risk factors for postoperative adverse events. Antibiotic treatment was an independent protective factor. CONCLUSION:This study showed the efficacy of sac filling with rifampin after endovascular repair in treating brucellosis-associated pseudoaneurysm. CRP level and the percentage of neutrophils are independent risk factors for postoperative adverse events and should be considered before endovascular repair. In addition, antibiotic treatment should be provided to reduce the occurrence of postoperative adverse events.

ABSTRACT Atherosclerosis (AS) is the basis of cardiovascular diseases (CVDs) and remains the major contributor to death worldwide. Capsiate is derived from sweet pepper fruit and exhibits numerous pharmacological activities. The objective of this study was to elucidate the protective role of capsiate in atherosclerosis by examining its effect and the underlying regulatory pathways. Here, we showed that capsiate treatment alleviates atherosclerosis in atherosclerosis-prone apolipoprotein E-deficient (ApoE−/−) mice. We found that capsiate effectively reduced the plaque area and body weight compared to the Model group. Capsiate inhibited inflammatory response by downregulating phosphoinositide 3-kinase/protein kinase B/nuclear factor-κB pathway. Additionally, further investigation indicated that capsiate could regulate lipid levels in mice via reducing the expressions of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low-density lipoprotein receptor, and increasing the expression of recombinant cytochrome P450 7A1. Furthermore, capsiate effectively activated transient receptor potential vanilloid subfamily member 1 in ApoE−/− mice fed a high-fat diet. The microbial sequencing demonstrated capsiate administration significantly regulated the gut microbiota disturbance and increased some beneficial bacterial (Lachnospiraceae NK4A136 group) levels in ApoE−/− mice. Human umbilical vein endothelial cells (HUVECs) were exposed to oxidized low-density lipoprotein (ox-LDL) to stimulate atherosclerotic endothelial damage in vitro. Our study revealed that capsiate inhibited ox-LDL-induced HUVECs injury and inflammation. We further investigated the effects of capsiate on ferroptosis in vivo and in vitro; it was found that capsiate exhibited anti-ferroptosis through regulating nuclear factor erythroid 2-related factor 2/glutathione peroxidase 4 pathway. Interestingly, ML385 reversed the anti-ferroptosis effect of capsiate in HUVECs. Taken together, our findings suggest a promising use of small-molecule drug capsiate for the treatment of AS and related CVDs.IMPORTANCECapsiate has been found to inhibit fat accumulation, promote energy metabolism, and exhibit anti-inflammatory and antioxidative properties. However, there has still been no study on the ferroptosis and gut microbiota of capsiate in atherosclerosis (AS) mouse models. Our study is the first to report on the reshaping of the structure of the gut microbiota by capsiate in AS, and to explore the potential mechanism underlying the improvement of AS. In this study, we demonstrated that capsiate could effectively alleviate high-fat diet-induced AS in apolipoprotein E-deficient mice by inhibiting inflammatory response, improving serum lipid profiles, activating transient receptor potential vanilloid subfamily member 1 pathway, and suppressing ferroptosis. Moreover, the study reported the potential of gut microbiota as mediators of capsiate therapy for AS in animal models. Therefore, these findings may provide robust experimental support for the clinical use of capsiate for AS treatment.

To estimate the incidences of left renal vein (LRV) entrapment by right renal artery (RRA), a phenomenon primarily reported as case reports. The cross-sectional study consecutively screened renal vessel CT data of 38 (Renal) patients with nephropathy and 305 (Non-renal) patients with peripheral arterial diseases in a teaching hospital in northeast China between November 2018 and March 2023. The LRV compression by adjacent anatomical structures, including but not limited to RRA and multiple compression-related parameters, were investigated through multiplanar analysis of the CT data. The overall LRV entrapment rates by adjacent structures were 41.93

Objectives: Distal stent graft-induced new entry (dSINE) can occur after thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD). In this study we aimed to compare the effectiveness of restrictive bare stent (RBS), tapered stent graft (TSG), and non-TSG in TEVAR in preventing dSINE after a midterm follow-up.Methods: This retrospective cohort study included patients with TBAD who under-went TEVAR (June 2010 to December 2018). The occurrence of dSINE during follow-up was examined. Predictors of dSINE were determined using Fine-Gray regression with death as the competing event. Survival was evaluated using Cox proportional hazards regression.Results: Finally, 364 patients were included: 111 with non-TSG TEVAR, 125 with TSG TEVAR, and 128 with TEVAR with RBS. After 54.5 months, incidences of dSINE in the 3 groups were 12.61%, 4.80%, and 1.56%, respectively (P = .002). On Fine-Gray regression adjusted for clinically relevant covariates, the expansion mismatch ratio (subdistribution hazard ratio, 1.09; 95% CI, 1.07-1.12; P < .001) and complete false lumen thrombosis (subdistribution hazard ratio, 0.35; 95% CI, 0.13-0.94; P = .037) were identified as predictors of dSINE. The Cox proportional hazards regression analysis revealed that dSINE was not only a risk factor for aortic -related mortality (hazard ratio, 17.90; 95% CI, 3.27-98.12; P = .001), but also a pre-dominant risk factor for all-cause mortality (hazard ratio, 4.91; 95% CI, 1.66-14.52; P = .004).Conclusions: dSINE can happen in TBAD patients who undergo TEVAR. Thus, long-term surveillance is crucial. TSG and RBS had lower expansion mismatch ratios, which might help prevent dSINE.

ObjectivesThe Talos stent-graft has extended length to improve aortic remodeling, and distal porous design to decrease the rate of spinal cord ischemia. This study retrospectively analyzed its mid-term outcomes for uncomplicated type B aortic dissection in a multicenter study.MethodsThe primary safety endpoint was 30-day major adverse events, including all-cause mortality, dissection-related mortality, conversion to open surgery, and device-related adverse events. The primary efficacy endpoint was treatment success at 12 months post-operation, defined as no technical failure or secondary dissection-related reintervention. The survival status of the patients was visualized using the Kaplan-Meier curve. Aortic growth was assessed at four levels, and spinal cord ischemia was evaluated at 12 months.Results113 patients participated with a mean age of 54.4 (11.1) years and 71.7% (81/113) were male. The 30-day mortality was 0.9% (1/113), no conversions to open surgery or device-related adverse events were recorded. The 12-month treatment success rate was 99.1% (112/113), with no dissection-related reinterventions. There was no spinal cord or visceral ischemia at 12 months. At a median of 34 months follow-up, 9 further deaths were recorded and the 3-year survival rate was 91.7%. The percentage of aortic growth was 1.8% (2/111) at the tracheal bifurcation, 3.6% (4/111) below the left atrium, 6.0% (5/83) above the celiac artery, and 12.1% (9/74) below the lower renal artery. The total thrombosis rate of the false lumen at the stented segment was 80.5% (91/113).ConclusionsThe results showed satisfactory results of Talos stent-graft in terms of safety and efficacy. More data are needed to confirm the long-term performance.

Background: The purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or nonstented restenotic femoropopliteal atherosclerotic lesions. Methods: BIOLUX P-IV China is a prospective, independently adjudicated, multicenter, single -arm trial conducted in China. Patients with Rutherford class 2e4 were eligible, excluded were patients in which predilation resulted in severe (& GE; grade D) flow-limiting dissection or residual stenosis > 70%. Follow-up assessments were conducted at 1, 6, and 12 months. The primary safety end point was 30-day major adverse event rate and the primary effectiveness end point was primary patency at 12 months. Results: We enrolled 158 patients with 158 lesions. Mean age was 67.6 & PLUSMN; 9.6 years, diabetes was present in 53.8% (n = 85), and previous peripheral intervention/surgeries in 17.1% (n = 27). Lesions were 4.1 & PLUSMN; 0.9 mm in diameter and 74 & PLUSMN; 50 mm long with a mean diameter stenosis of 91 & PLUSMN; 13%; 58.2% (n = 92) were occluded (core laboratory analysis). Device success was achieved in all patients. The rate of major adverse events was 0.6% (95% confidence interval: 0.0; 3.5) at 30 days, consisting of 1 target lesion revascularization. At 12 months, binary reste-nosis was present in 18.7% (n = 26) and target lesion revascularization was performed in 1.4% (n = 2, all clinically driven), resulting in a primary patency of 80.0% (95% confidence interval: 72.4, 85.8); no major target limb amputation occurred. Clinical improvement at 12 months,

Backgrounds and ObjectivesDrug-coated balloons (DCBs) have shown promising benefits in improving the outcomes for patients with peripheral artery disease. Several randomized clinical trials have reported that paclitaxel-coated balloon significantly reduce the rates of restenosis and the need for reintervention in comparison with regular balloon angioplasty. Due to the differences in excipients, paclitaxel dose, and coating techniques, variable clinical outcomes have been observed with different DCBs. In this study, we aimed to evaluate the safety and efficacy of a novel ZENFlow carrier-free DCB in the treatment of femoropopliteal artery occlusive disease.MethodsIn this randomized controlled trial conducted at 15 sites, 192 patients with Rutherford class 3–5 were randomly assigned into two groups: drug-coated balloon group and percutaneous transluminal angioplasty group. The primary endpoint was a late lumen loss at 6 months based on blinded angiographic core laboratory evaluations, and the secondary endpoints included primary patency rate, binary restenosis, clinically driven target lesion revascularization, ankle-brachial index, Rutherford class change, and major adverse events.ResultsIn this multicenter trial, 93 patients received DCB angioplasty, whereas 99 patients underwent regular balloon angioplasty. The late lumen loss at 6-month follow-up was 0.50 ± 0.82 and 1.69 ± 0.87 mm in the drug-coated balloon and percutaneous transluminal angioplasty groups, respectively (p < 0.001). During the 12-month follow-up period, the drug-coated balloon group showed a significantly higher primary patency rate (54 vs. 31.3%, p = 0.009) and markedly lower rates of target vessel restenosis (22.1 vs. 64.3%, p < 0.001) and clinically driven target lesion revascularization rate (5.4 vs. 19.2%, p = 0.006) than the percutaneous transluminal angioplasty group. Compared with the percutaneous transluminal angioplasty group, the drug-coated balloon group had significant improvements in the ankle-brachial index and Rutherford class. The all-cause mortality rate was comparable, and no device-related deaths occurred in either groups.ConclusionsBalloon angioplasty using a ZENFlow carrier-free drug-coated balloon is a safe and effective treatment method for femoropopliteal artery lesions. This novel drug-coated balloon catheter achieved satisfactory early and 1-year outcomes in this trial.Clinical Trial Registrationhttps://clinicaltrials.gov, identifier: NCT03844724.

随着手术器械的不断改良和手术技术经验的不断累及,主动脉腔内修复术(thoracic endovascular aortic repair,TEVAR)由于其微创、机体损伤小、机体恢复快、术后的死率低等特点,已经成为治疗主动脉疾病的主要医治手段[1-2].尽管如此,这些支架的远期效果仍存在忧虑.对于StanfordB型主动脉夹层(stanford B aortic dissection,TBAD),无论急性期还是慢性期,TEVAR都能很好的降低患者的死亡率,但对于TEVAR术后支架的长期效果、支架内漏、支架源性新发破口等问题越来越多的被人重视[5].支架诱导的新发破口(stent graft-induced new entry tear,SINE)被定义为支架本身引起的内膜撕裂,不包括自然疾病进展或血管内医源性的损伤[2].尤其是在TBAD中,这些破口可能发生在移植物的近端或远端,当新发破口形成时,近段的SINE容易形成逆行A型夹层(retrograde type A aortic dissection,RTAD)[4];远端的SINE (dSINE)可以发展为一个明显的假腔,随后动脉瘤扩张和破裂的可能[3].自从Kato等[3]第一次报道出dSINE,国内外对TEVAR术后dSINE的有关危险因素及处理方法进行了大量的研究,甚至得出发生dSINE的病死率高达25％[2,7-8].通过回顾既往文献,对Stanford B型夹层术后dSINE发生的有关危险因素及防治措施进行综述.

随着手术器械的不断改良和手术技术经验的积累, TEVAR 因其创伤小、住院时间短、恢复快、术后死亡率低等特点,成为主动脉疾病的主要治疗手段[1, 2].无论是急性期还是慢性期的Stanford B型主动脉夹层(type B aortic dissection,TBAD), TEVAR都能很好地降低手术死亡率,但远期效果仍存在忧虑,术后支架植入的长期效果、内漏、支架源性新发破口等问题越来越得到重视[3].支架诱导的新发破口(stent-graft induced new entry,SINE)被定义为支架本身引起的内膜撕裂,不包括自然疾病进展或血管内医源性的损伤 [2].TBAD的SINE可能发生在移植物的近端或远端,近段容易形成逆行 A 型主动脉夹层[4],远端的 SINE (distal stent-graft induced new entry,dSINE)可发展为一个明显的假腔,随后可能出现动脉瘤扩张和破裂[5].本文通过回顾既往文献,对TBAD术后dSINE发生的危险因素及防治措施进行综述并报告如下.

目的:研究主动脉腔内修复术(TEVAR)联合远端限制性支架(RS)治疗B型主动脉夹层的中、远期临床效果.方法:对2010年6月至2018年12月,哈尔滨医科大学附属第二医院血管外科接受TEVAR或TEVAR+RS治疗的B型主动脉夹层患者资料进行回顾性分析.结果:共239例患者纳入研究,男性185例,女性54例,年龄24～80岁,平均年龄(54.2±10.7)岁.TEVAR组111例,TEVAR+RBS组128例.手术成功率100％.TEVAR+RS组较TEVAR组支架远端新发破口(dSINE)发生率明显降低[14/111(12.6％)vs.2/128(1.6％),P=0.0007],同时主动脉假腔重构也明显优于TEVAR组.结论:应用胸主动脉腔内修复术联合RS治疗B型主动脉夹层,不仅能够有效地减少dSINE发生,并且有利于主动脉夹层假腔重构,具有良好的中-长期疗效.

目的 总结混合现实技术(mixed reality,MR)在血管外科领域中的研究进展.方法 检索国内外有关MR应用于血管外科的基础与临床研究相关文献,就其研究进展进行综述.结果 MR应用于血管外科极大地提高了医疗教育标准化,缩短了学习周期,有效缩短了手术时间,增加了患者获益.MR在血管外科的应用尚处于起步阶段,在展现出诱人前景的同时也暴露出一些不足之处.结论 MR在血管外科的应用尚处于探索阶段,但前景诱人,随着注册技术的不断提高,精度的不断完善,MR会越来越广泛地应用于血管外科.

下肢动脉腔内治疗是下肢动脉硬化闭塞症患者的常用治疗方法.球囊扩张加支架植入的治疗方式因其再狭窄(ISR)率较高,而不能令人满意.ISR严重影响支架术后患者的预后和生活质量,发生ISR患者往往需要二次手术,但由于费用高、远期通畅效果不佳、支架断裂等一系列问题,预防ISR发生显得尤为重要.舒洛地特对全身血管系统具有广泛的生物学效应,其抗炎、抗血栓、保护血管内皮等作用对防治ISR可能可起到重要作用.笔者就ISR目前诊治的现状及舒洛地特在ISR治疗的应用前景进行综述.

Atherosclerosis (AS) is a chronic inflammatory disease that mainly involves the large and middle arteries, but the specific mechanism is not precise. Chemokine ligand 19 (CCL19) has been reported highly expressed in peripheral blood of patients with atherosclerosis, but its role lacks explicit data. By ELISA assay and immunohistochemical (IHC) analysis, we found that the CCL19 was significantly up-regulated in AS. Therefore, we tried to clarify whether CCL19 expression was related to the progression of AS. QRT-PCR and western blot demonstrated that overexpression of CCL19 promoted the secretion of inflammatory factors and the deposition of the extracellular matrix, and facilitated the proliferation and migration of VSMCS. Besides, knockdown of CCL19 reduced the inflammation, collagen secretion, proliferation and migration of VSMCS induced by PGDF-BB. The results of database analysis, chromatin immunoprecipitation (ChIP) and luciferase assay showed that interferon regulatory factor 1 (IRF-1) activated the expression of CCL19 at the transcriptional level. Importantly, silencing IRF-1 inhibited atherosclerosis in high-fat-fed mice, inhibited the proliferation and migration of VSMCS, and down-regulated the expression of CCL19. Summing up, the results demonstrated that IRF-1 contributed to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription.

目的:观察通过电凝法处理下肢病理性穿通静脉对慢性下肢静脉功能不全的治疗效果,评估该方法的有效及安全性.方法:纳入了单纯性下肢静脉曲张患者125例(188条患肢),病理性穿通静脉接受了经皮穿刺套管针电凝术,大隐静脉主干接受射频消融术.观察术后下肢临床表现的恢复程度,以及并发症发生率.结果:术后1周,3个月和6个月时患者的静脉临床严重程度评分(VCSS评分)较术前均有显著下降,尤其表现在溃疡的愈合情况(P＜0.05).未出现例如下肢静脉血栓形成等任何并发症.结论:病理性穿通静脉电凝治疗对促进下肢慢性静脉功能不全导致的皮肤病损和溃疡的愈合安全有效.

Purpose: To confirm the safety and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) as a treatment for de novo and native artery restenotic lesions in the superficial femoral artery (SFA) and/or proximal popliteal artery in Chinese subjects. Materials and Methods: IN.PACT SFA China (ClinicalTrials.gov identifier NCT02118532) was a single-arm, independently adjudicated, prospective, premarket study that enrolled 143 subjects (mean age 66.8±7.7 years; 107 men) at 15 centers. The predominant risk factors were hypertension (104, 72.7%) and diabetes mellitus (66, 46.2%). The majority of subjects were classified as Rutherford category 2 or 3 [69 (48.3%) and 55 (38.5%), respectively]; 19 (13.3%) subjects had critical limb ischemia (Rutherford category 4). The mean lesion length was 10.4±6.51 cm; more than half of the lesions (75, 52.4%) were chronic total occlusions. Calcification was found in 66 (46.2%) lesions. Outcomes at 12 months were compared with DCB safety and effectiveness performance goals derived from the literature. The 30-day primary safety outcome was a composite of freedom from device- and procedure-related mortality, major target limb amputation, and clinically-driven target lesion revascularization (CD-TLR). Results: The primary safety outcome was 99.3% at 30 days. Follow-up compliance at 12 months was 92.6%. Estimated 1-year primary patency using Kaplan-Meier analysis was 90.9% and freedom from CD-TLR was 97.1%. The rate of CD-TLR at 12 months was 2.9%. The Rutherford category status improved significantly (p<0.001) between baseline and 12 months. Conclusion: Results from IN.PACT SFA China demonstrated high rates of patency and low rates of CD-TLR in Chinese subjects through 12 months despite patient and lesion complexity. These data are consistent with the results of other IN.PACT DCB trials.

The objective of this study was to investigate the efficacy and safety of a novel paclitaxel-coated balloon catheter in the treatment of chronic atherosclerotic occlusive disease in femoropopliteal arteries. Patients with peripheral artery occlusive disease undergoing percutaneous transluminal angioplasty were prospectively randomized to novel carrier-free ZENFlow (Zhejiang Zylox Medical Device Co Ltd, Hangzhou, China) paclitaxel drug-coated balloon (DCB) group or plain balloon angioplasty (PBA) group. The primary end point was late lumen loss at 6 months assessed by blinded angiographic core laboratory quantitative analyses. Secondary end points included primary target vessel patency at 12 months, binary restenosis, target lesion revascularization, target vessel revascularization, Rutherford class change, and ankle-brachial index (ABI) at 6 months. There were 192 Chinese patients who were randomized in 15 hospitals (93 to DCB and 99 to PBA). The mean age of patients was 68 years; 71.9% were male, and 50.5% were smokers. No significant differences were identified between the groups in terms of baseline patient demographics, comorbidities, Rutherford class, and ABI. Mean lesion length was 62.5 mm; 12.7% had in-stent restenosis, and 37% of lesions were total occlusion. In total, 23 (12%) patients underwent bailout stenting because of flow-limiting dissection after balloon angioplasty. After 6 months, late lumen loss in the DCB and PBA groups was 0.80 ± 0.71 mm and 1.69 ± 0.87 mm (P < .0001), respectively. Primary target vessel patency rate was significantly higher in the DCB group than in the PBA group (54% vs 31.3%; P = .0091) at 12 months. Target vessel restenosis rate was dramatically lower in the DCB group than in the PBA group (16.3% vs 54.6%; P < .0001), as were target lesion revascularization (8.8% vs 27.1%; P = .052) and target vessel revascularization (11.8% vs 30%; P = .0086) at 6 months. Significant improvement in Rutherford class was found in the DCB group compared with the PBA group (P = .0385). Postoperative ABI was markedly increased in the DCB group than in the PBA group (0.89 ± 0.27 vs 0.78 ± 0.28; P = .0182) after 6 months. There were no definitely device-related deaths or major adverse events in either group. Balloon angioplasty using the ZENFlow DCB catheter is a safe and effective method for the treatment of chronic occlusive lesions in the femoropopliteal artery and can achieve satisfactory early and midterm outcomes compared with regular balloon angioplasty.

Background Despite being one of the most common benign tumors, the prevalence and pathogenesis of hemangiomas (HAs) are poorly understood. We aimed to identify the biological role of the long non-coding RNA (lncRNA) CASC9 in the HA-derived endothelial cell (HDECs) phenotype as well as elucidate the mechanism involved. Methods The expression of CASC9 was identified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). the effect of CASC9 on cell proliferation, migration and invasion of HDECs were examined by CCK8, wound healing, and transwell assay, respectively. Bioinformatics analysis and a luciferase reporter assay were utilized to investigated the mechanisms involved. The in vivo tumorigenesis capability of CASC9 on HA was also evaluated. Results The expression of CASC9 was significantly elevated in HA tissue compared to normal tissue. Down-regulation of CASC9 inhibited proliferation, migration, and invasion of HDECs. The translation of cyclinD1, N-cadherin, Twist, and MMP2 was also decreased by CASC9 knockdown treatment. Furthermore, CASC9 over-expression exerted the opposite effect of proliferation, migration, and invasion of HDECs. We also found that CASC9 interacts with miR-125a-3p/Nrg1 to regulate cellular functions. Interestingly, miR-125a-3p can reverse the effect of CASC9 on proliferation, migration, and invasion of HDECs. Together, the clinical data showed that CASC9 expression is negatively correlated with miR-125a-3p expression and positively correlated with Nrg1 expression. CASC9 also exerted anti-tumorigenesis capability in vivo. Conclusion Our study indicates that CASC9 accelerates cell growth and invasion of HDECs and provides new insights for the diagnosis and molecular therapy of HA.